Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David N Assis

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Hepatology (Baltimore, Md.)|June 6, 2020
Immunosuppressive Treatment Regimens in Autoimmune Hepatitis: Systematic Reviews and Meta-Analyses Supporting American Association for the Study of Liver Diseases GuidelinesJohn M Vierling, Nanda Kerkar, Albert J Czaja, et al.
Ebiomedicine|August 11, 2023
Advancing diagnosis and management of liver disease in adults through exome sequencingMelanie Zheng, Aaron Hakim, Chigoziri Konkwo, et al.
Case Reports in Oncology|April 1, 2021
Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case ReportBrendan John Guercio, Gopa Iyer, Wajih Zaheer Kidwai, et al.
Hepatology Communications|January 29, 2024
African American race does not confer an increased risk of clinical events in patients with primary sclerosing cholangitisMaryam Yazdanfar, Joseph Zepeda, Richard Dean, et al.
Hepatology (Baltimore, Md.)|November 7, 2023
Cystic fibrosis screening, evaluation, and management of hepatobiliary disease consensus recommendationsZachary M Sellers, David N Assis, Shruti M Paranjape, et al.
Nature Communications|February 9, 2023
Unique DUOX2<sup>+</sup>ACE2<sup>+</sup> small cholangiocytes are pathogenic targets for primary biliary cholangitisXi Li, Yan Li, Jintao Xiao, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 18, 2019
Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel DiseasesKate D Lynch, Roger W Chapman, Satish Keshav, et al.
Hepatology (Baltimore, Md.)|March 13, 2021
Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter StudyCumali Efe, Renumathy Dhanasekaran, Craig Lammert, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 10, 2025
Hepatic Encephalopathy and MELD-Na Predict Treatment Benefit in Autoimmune Hepatitis-related Decompensated CirrhosisPinelopi Arvaniti, Sergio Rodríguez-Tajes, Marlene Padilla, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 30, 2021
Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitisCumali Efe, Craig Lammert, Koray Taşçılar, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Hepatology (Baltimore, Md.)|June 6, 2020
Immunosuppressive Treatment Regimens in Autoimmune Hepatitis: Systematic Reviews and Meta-Analyses Supporting American Association for the Study of Liver Diseases GuidelinesJohn M Vierling, Nanda Kerkar, Albert J Czaja, et al.
Ebiomedicine|August 11, 2023
Advancing diagnosis and management of liver disease in adults through exome sequencingMelanie Zheng, Aaron Hakim, Chigoziri Konkwo, et al.
Case Reports in Oncology|April 1, 2021
Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case ReportBrendan John Guercio, Gopa Iyer, Wajih Zaheer Kidwai, et al.
Hepatology Communications|January 29, 2024
African American race does not confer an increased risk of clinical events in patients with primary sclerosing cholangitisMaryam Yazdanfar, Joseph Zepeda, Richard Dean, et al.
Hepatology (Baltimore, Md.)|November 7, 2023
Cystic fibrosis screening, evaluation, and management of hepatobiliary disease consensus recommendationsZachary M Sellers, David N Assis, Shruti M Paranjape, et al.
Nature Communications|February 9, 2023
Unique DUOX2<sup>+</sup>ACE2<sup>+</sup> small cholangiocytes are pathogenic targets for primary biliary cholangitisXi Li, Yan Li, Jintao Xiao, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 18, 2019
Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel DiseasesKate D Lynch, Roger W Chapman, Satish Keshav, et al.
Hepatology (Baltimore, Md.)|March 13, 2021
Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter StudyCumali Efe, Renumathy Dhanasekaran, Craig Lammert, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 10, 2025
Hepatic Encephalopathy and MELD-Na Predict Treatment Benefit in Autoimmune Hepatitis-related Decompensated CirrhosisPinelopi Arvaniti, Sergio Rodríguez-Tajes, Marlene Padilla, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 30, 2021
Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitisCumali Efe, Craig Lammert, Koray Taşçılar, et al.
Pageof 6